| > Dr. Ashok K. Srivastava
Dr. Srivastava’s laboratory has provided novel insights on
the mechanism of antidiabetic and insulinomimetic effects of vanadium-based
protein tyrosine phosphatase inhibitors. They have discovered that
insulin-like effects of these compounds are exerted through an insulin
receptor-independent process. They have also demonstrated an essential
role of insulin-like growth factor receptor (IGF1-R) transactivation
in triggering organo-vanadium compound-induced gluco-regulatory
signal transduction pathway in liver derived cells.
Dr. Srivastava’s laboratory has also demonstrated that reactive
oxygen species (ROS) modulate insulin, vanadium, and vasoactive
peptide-induced signal transduction pathways and thereby suggested
an involvement of oxidative stress-induced signalling events in
cardiovascular complications of diabetes. Ongoing studies along
these lines in his laboratory would help to identify new targets
to develop novel therapies for diabetes.
Dr. Srivastava has trained many M.Sc. and Ph.D. students. Currently,
there are two M.Sc. and two Ph.D. students in Dr. Srivastavas laboratory.
PhD students in his laboratory are supported by FRSQ and Pfizer/CHS/CIHR-Rx&D
Doctoral Research Awards.
Dr. Ashok K. Srivastava
Dr. Ashok K. Srivastava is a Professor at the
Department of Medicine, Université de Montréal, and
Head of the Laboratory of Cell Signaling at the Research Center
of the Centre hospitalier de l’Université de Montréal
(CHUM). He obtained his Ph.D. degree in 1974 from Kanpur University,
Kanpur, India, based on the research done at the Central Drug Research
Institute in Lucknow, India. Dr. Srivastava received post-doctoral
training at the Department of Biochemistry, University of Southern
California, Los Angeles, and at the Vanderbilt University, Nashville,
Tennessee. In 1981, he joined the Clinical Research Institute of
Montreal as a Senior Investigator in the Diabetes and Metabolism
research group. In 1992, Dr. Srivastava moved to the Research Center
of the CHUM as a Research Scientist. In 1998, he was appointed Associate
Professor of Medicine at the Université de Montréal,
and was subsequently promoted to Professor of Medicine in 2005.
Dr. Srivastava has published more than 60 full-length
papers, 11 book chapters and has edited 3 books. He has contributed
in the training of many graduate students and post-doctoral fellows.
He is a member of several scientific societies, including the American
Society of Biochemistry and Molecular Biology, the Canadian Society
of Biochemistry and Molecular Biology, and the International Society
for Heart Research. Dr. Srivastava has served or is serving as a
guest editor of many journals, such as Antioxidant and Redox Signaling,
Canadian Journal of Physiology and Pharmacology, Cell Biochemistry
and Biophysics and Molecular and Cellular Biochemistry, and is currently
a member of the editorial board of Advances in Biochemistry in health
and disease. He has also organized several International symposia
and workshops, and also serves on the grant review panels of the
Canadian Institutes of Health Research, the Heart and Stroke Foundation
and the National Institutes of Health.